Boehringer Ingelheim GmbH, of Ingelheim, Germany, presented results from a phase II study in Crohn's disease at Digestive Disease Week in San Diego, showing that risankizumab (formerly BI 655066), a compound recently licensed by Abbvie Inc., of North Chicago, was found to be more effective than placebo in patients with moderately to severely active Crohn's.